Santarus appoints Wendell Wierenga executive vice-president
This article was originally published in Scrip
Executive Summary
Santarus, a speciality biopharmaceutical company, has appointed Dr Wendell Wierenga executive vice-president of R&D. In this role, Dr Wierenga will oversee clinical research, regulatory affairs, quality assurance, medical affairs and pharmacovigilance. He was previously executive vice-president of R&D for Ambit Biosciences Corporation, and currently serves on the boards of Cytokinetics, Onyx Pharmaceuticals and XenoPort.